Centre Oscar Lambret — Clinical Trial Site

273 Registered trials

137 Currently recruiting

Organisation

Centre Oscar Lambret

Location

Lille, France

Identifier

ORG-100008539

Address

3 Rue Frederic Combemale, 59000, France

Departments

105: Cancérologie Générale
2314: Centre Oscar Lambret
59
Canc. Chir. Gyn., Pavillon Paul Gellé
cancérologie
Cancérologie Gynécologique
Cancérologie Sénologique
Cervico-facial and thoracis onclogy and gynaecology
Cervico-facial and thoracis oncology
Chirurgie Digestive
Chirurgie gynécologique
Departament oncologie
Departement d'Oncologie Medicale
Département d’Oncologie Médicale
Département de cancérologie Cervico-Faciale
Département de Cancérologie Gynécologie
Département de Cancérologie Gynécologique
Département de Cancérologie Sénologique
Département de radiothérapie
Département Oncologie Générale
Department of Anesthesia, Intensive Care, and Pain Management
Department of Cervico-facial and thoracis oncology and Department of gynaecology
Department of onco-Gynaecology
Department of Oncology, Pediatric unit
Dept. of Oncology
Digestive Oncology
Direction de la Recherche Clinique et de l'innovation
Direction de la Recherche Clinique et de l'Innovation (DRCI) - medical oncology
DRCI
DRCI Investigation
Gastroenterology and digestive cancer department
General Oncology
Gynecological surgery
Gynécologie
Head and neck surgery
Hôpital Oscar Lambret
Medical oncology
Medical Oncology - Gastroenterology and Urology
Medical Oncology – Breast Committee
Medical Oncology Department
Medical oncology department in Pediatrics
N/A
NA
Nord
Nuclear medicine
Onco-pédiatrie
Onco-Urology Department #1505
Oncologie
Oncologie générale
Oncologie Médical
Oncologie Medicale
Oncologie Médicale - Gastroentérologie et urologie
Oncologie médicale pôle digestif
ONCOLOGIE OPTION MEDICALE
Oncologie Radiothérapie
Oncologue
oncology
Oncology department
Oncology for pediatrics
Oncology service
ORL
ORL and Facial Surgery
ORL et Chirurgie cervico-faciale
Paediatric Oncology
Ped Oncology
Pediatric oncology
Pediatric oncology department
Pediatric unit - Oncology
Pediatric unit, oncology department
Pediatric Unit. Oncology department
Pediatrics
pediatrie
Pôle d'Oncologie Médicale
Pôle oncologie
Pole Oncologie médicale
Pôle oncologie, comité CCFT
Pôle oncologie, comité pédiatrique
Pôle oncologie, comité sénologique
Radiation Oncology
Radiothérapie
Radiotherapist
Radiotherapy
Radiotherapy for adults
Radiotherapy for pediatrics
Radiotherapy Oncology
Senology
Service d'Oncologie médicale
Service d’Oncologie Générale
Service de Cancérologie Générale
Service de radiothérapie
Unité d'Oncologie Pédiatrique
Unité d’Onco-Pédiatrie
Unité d’Oncologie pédiatrique, Centre Oscar Lambret de Lille Centre régional de lutte contre le canc
Unité de Pédiatrie
Urological and Digestive Oncology

Clinical trials at this site (273)

Search interface

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Ended

2024-514904-14-00 Patients with metastatic or unresectable locally advanc 4 2014-10-08
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended

2024-513455-33-00 Bone sarcoma 4 2014-09-11
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated Ended

2024-514844-10-00 Retinoblastoma 4 2010-03-18
Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended

2024-514756-32-00 High grade osteosarcoma 5 2007-03-19
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma… Halted

2023-510559-41-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2025-01-02
Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO Halted

2024-513535-24-00 Refractory or Recurrent Solid Tumor 9 2022-05-02
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase… Halted

2024-513576-18-00 Cervical Cancer 5 2020-07-17
An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, ti… Ended

2024-516717-20-00 Metastatic non small cell lung cancer (Phase I and expa 3 2024-11-27
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig… Ended

2023-508356-19-00 Pancreatic adenocarcinoma metastatic 4 2024-06-25
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended

2023-506823-28-00 Adult patients with locally advanced/metastatic solid t 4 2024-06-14
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 recurrent or persistent uterine serous carcinoma 4 2024-05-22
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended

2023-503223-26-00 Advanced Solid Tumors Harboring a KRASG12C Mutation 9 2024-05-07
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended

2023-503739-16-00 Relapsed or refractory solid tumors or non-Hodgkin lymp 1 2023-12-20
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C… Ended

2023-503270-20-00 recurrent or metastatic Adenoid Cystic Carcinoma of the 3 2023-11-29
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended

2022-502339-20-00 Squamous cell carcinoma of head and neck 4 2023-11-15
A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended

2023-505627-30-00 Solid Neoplasm 7 2023-07-26
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended

2024-515552-21-00 Recurrent or refractory neuroblastoma. 3 2023-04-17
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien… Ended

2022-501363-40-00 Advanced or metastatic solid tumors with a KRAS-G12C mu 3 2023-03-17
OMX-0407 Phase I Study Ended

2024-514554-75-00 Previously treated unresectable solid tumours 1 2023-03-16
SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease Ended

2024-511713-38-00 Cisplatine induced hearing loss 4 2022-12-30
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16